DiscoverPeerVoice Endocrinology & Metabolic Disorders VideoJohn E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes
John E. Anderson, MD /  Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes

John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes

Update: 2025-12-23
Share

Description

Visit https://www.peervoice.com/FTR860 to view the entire programme with slides. After completing “John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes”, participants will be able to: Summarize the complications, burden, and unmet needs associated with the diagnosis and management of hypercortisolism; Describe the mechanistic rationale associated with new and emerging therapies in hypercortisolism; Recall safety and efficacy data relating to new and emerging treatment strategies in patients with hypercortisolism; and Appraise recent data regarding newer therapies in the context of current approaches to the management of difficult-to-treat metabolic disease.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

John E. Anderson, MD /  Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes

John E. Anderson, MD / Richard J. Auchus, MD, PhD - Hypercortisolism and Difficult-to-Treat Cardiometabolic Disease: Therapeutic Developments and Clinical Advances Driving Meaningful Improvement in Patient Outcomes

PeerVoice